Activating genetic variants in the EGFR gene, qualifying for treatment with EGFR inhibitors (erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib) are observed in 10–15% of Caucasian patients and in at least 40% of Asian non-small cell lung cancer (NSCLC) patients [4]. Here, EGFR is linked to non-small cell lung carcinoma.